Mumbaistatin, a process for it's production and its use as a pharmaceutical

US6297043A · kind A · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Nirogi Venkata Satya Ramakrishna · Hyderabad, IN
• Keshavapura Hosamane Sreedhara Swamy · Mumbai, IN
• Erra Koteswara Satya Vijaya Kumar · Mumbai, IN
• Manoj Maniram Singh Kushwaha · Thane, IN
• Sridevi Kota · Mumbai, IN
• Mythili Raman · Mumbai, IN
• Swati Dhananjay Tare · Mumbai, IN
• Sunil Kumar Jaiwant Rao Deshmukh · Jamkhed, IN
• Dietmar Schummer · Langen, DE
• Michael Kurz · Neustadt, DE
• Herbert Kogler · Königstein, DE

Key dates

• Filing date: Jun 23, 1999
• Grant date: Oct 2, 2001
• Expiry date: Jun 23, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/886
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound named Mumbaistatin, its pharmaceutically acceptable salts and derivatives, a process for its production, and its use as a pharmaceutical. Mumbaistatin is obtainable by cultivation of the microorganism HIL-008003 (DSM 11641). Mumbaistatin is a glucose-6-phosphate translocase inhibitor and can be used in the treatment of diabetes mellitus. The present invention further relates to a process for the production of Mumbaistatin, to the microorganism HIL-008003 (DSM 11641), to the use of Mumbaistatin and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use in the treatment of diabetes mellitus, and to pharmaceutical compositions comprising Mumbaistatin or a pharmaceutically acceptable salt or derivative thereof.